Dr. Christian Behrenbruch, Group CEO and Managing Director of Telix Pharmaceuticals said, "This is an important technological development for patients and medical teams alike. PSMA-PET imaging has been one of the most important developments in prostate cancer detection and nuclear medicine in recent years – and is already being rapidly adopted by medical teams managing men with prostate cancer. We're excited to explore this approach to total-body PSMA-PET imaging with BAMF Health and to demonstrate our shared commitment to ongoing innovation in this field."
Dr. Harshad Kulkarni, BAMF Health Chief Medical Advisor, said, "At BAMF Health we are focused on bringing new theranostic technologies and treatment options to patients in the United States. This partnership brings together imaging hardware technology and radiopharmaceutical developments. The uEXPLORER has the potential to offer increased sensitivity and faster scan time. These efficiencies may help get patients vital information about their cancer and allow us to see more patients in need. The uEXPLORER may be useful for medical teams managing a high volume of patients, and for patients who prefer less time in a PET/CT."
Ad Statistics
Times Displayed: 113072
Times Visited: 6738 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Prostate cancer is the second-most common cancer among men in the United States. According to the American Cancer Society, more than 268,000 men in the U.S. will be affected this year by prostate cancer, and nearly 35,000 will die from the disease. Reliable and accessible diagnostic tools are essential for treatment teams in narrowing the gap between accurate staging and appropriate individualized treatment by health care professionals.
About Illuccix
Telix's lead product, Illuccix® (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),[6] and by the Australian Therapeutic Goods Administration (TGA).[7] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[8] and Canada.[9]
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
